Podcasts about CHF

Can compassion ministry and gospel proclamation work together? In this episode of The Missions Show, Alex and Scott sit down with Dave Phillips, founder and president of Children's Hunger Fund (CHF), to explore the relationship between gospel proclamation, mercy ministry, and the local church. Dave shares the remarkable story behind CHF's founding, beginning with a life-changing visit to a pediatric cancer ward in Honduras and culminating in a providential donation of life-saving medicine that confirmed God's call to launch the ministry. What started as a small step of faith has grown into a global ministry serving suffering children and families through partnerships with local churches in more than 30 countries. The conversation also tackles some of the most important debates in modern missions: the balance between word and deed ministry, the dangers of prosperity theology, the role of parachurch organizations, and how churches can engage in poverty alleviation without undermining local congregations. Key Topics Dave Phillips' testimony and the founding story of Children's Hunger Fund How God used a providential donation of cancer medication to confirm CHF's mission The relationship between gospel proclamation and mercy ministry Why addressing spiritual poverty must remain central to poverty alleviation efforts The biblical role of the local church versus parachurch organizations in missions Lessons from When Helping Hurts, short-term missions, and serving the poor with sound theology Do you love The Missions Show? Have you been blessed by the show? Then become a Premium Subscriber! Premium Subscribers get access to: Exclusive bonus content A community Signal thread with other listeners and the hosts Invite-only webinars A free gift! Support The Missions Show and sign up to be a Premium Subscriber at missionsshow.com/premium The Missions Show is powered by ABWE. Learn more and take your next step in the Great Commission at abwe.org. Want to ask a question or suggest a topic? Email alex@missionsshow.com.

Orgie, Gangbang, Bukkake, Daisy Chain und Co. Gruppensex ist mehr als ein Porno-Klischee. Wir schauen auf psychologische Hintergründe, gelernte sexuelle Skripts, biologische Modelle (Stichwort "Spermienkonkurrenz") und Gruppendynamiken. Eine Folge zwischen Forschung, Fantasie und der Frage, wie Sexualität in Gruppen überhaupt funktioniert.--------Die erotische Audio-Plattform femtasy ist unser heutiger Werbepartner. So profitierst du von unserem Special Deal:

In dieser Folge zeige ich euch mein Depot-Update für Mai, in dem "Sell in May" absolut unbegründet war. Mein Portfolio steht trotz einer leichten Underperformance in diesem Jahr bei starken 1,33 Millionen Schweizer Franken. Durch bereits 9500 Franken an gesammelten Dividenden und Prämien läuft mein Cashflow dennoch hervorragend. Abschließend lade ich euch herzlich zu unserem Community-Treffen am 10. Juli 2026 in Zürich ein.

An informed source to Al Arabiya said the agreement on the release of frozen Iranian funds in its final stages, but the search continues for a mechanism on frozen funds. However, US President Trump informed the mediators of his refusal to release funds to Iran before signing the agreement.Israel and Lebanon agreed to a ceasefire in US-brokered talks, with the ceasefire contingent on Hezbollah's evacuation from the Litani. Despite this, there have been reports of continuing attacks in Southern Lebanon.US equities mixed as disappointing AVGO and CRWD earnings weigh on NQ and ES. Fixed income benchmarks gain by a handful of ticks ahead of Friday's NFP.DXY softened; JPY saw fleeting strength following hawkish BoJ reports, CHF firmer despite softer CPI data.Crude slips as efforts for a US-Iran deal continue.Looking ahead, highlights include Jobless Claims (May/30), Revelio PLS (May), Chicago Fed Labor Market Indicators Final (May), Speakers include BoE's Bailey, Fed's Daly, Bowman & Barkin, Earnings from Docusign, lululemon & Ciena.Read the full report covering Equities, Forex, Fixed Income, Commodites and more on Newsquawk

Chief Fixed Income Strategist Vishy Tirupattur takes a look at how credit markets are adapting to fund the new phase of AI capex.Read more insights from Morgan Stanley.----- Transcript ----- Welcome to Thoughts on the Market. I am Vishy Tirupattur, Morgan Stanley's Chief Fixed Income Strategist. Today – The critical question behind the AI-driven capex cycle that is front and center for markets year to date. How is credit market financing this ecosystem evolving? It's Wednesday June 3rd at 2 pm in New York. When we first discussed the role of credit markets in financing the AI and data center build-out around the middle of last year, the direction of travel was clear. Realizing the transformative potential of AI requires unprecedented levels of capex. What has really surprised us since is the scale and speed of that spending, both of which have exceeded our expectations by a wide margin. The upward revision to capex expectations has been dramatic. A year ago, we projected the combined capex of the five large hyperscalers at roughly $450 billion in both 2026 and 2027. After the first quarter earnings reports, Morgan Stanley's internet equity analysts, led by Brian Nowak, now expect hyperscaler capex of roughly $800 billion in 2026 and $1.2 trillion in 2027. One data point really captures the surge in the underlying demand for compute. According to OpenRouter, the global weekly token usage, which is a key proxy for compute, has risen by roughly 350 percent since early January, increasing from about 6 trillion tokens to 28 trillion tokens. Credit channels for financing this capex have not only been broader and deeper than we anticipated, spanning public and private markets, but have seen remarkable in the structural innovation that is blurring the lines between public and private markets. Over $200bn of public AI-related issuance across the different credit channels has happened just in the first five months of this year. We had previously assumed unsecured issuance would be limited by the scale of the largest non-financial issuers, confined to investment grade credit only, and largely USD denominated. Instead, some hyperscaler issuance has now far exceeded even the largest telecom names; funding has expanded well beyond USD into EUR, GBP, CHF, JPY and CAD markets. The issuer base has also broadened to include data center REITs and neoclouds, particularly in the high-yield market. The scope of financing has also widened beyond the data center shells themselves. GPU financing, which we assumed would be funded entirely through equity capital, has begun to migrate into credit markets. Funding is now coming through broadly syndicated loans and asset based financing, with ABS structures not far behind. Structural innovation illustrates how rapidly the credit ecosystem is adapting to the complexities of demands of AI-driven capex. Financings that combine elements of project finance, tranching, and residual value guarantees, along with high-yield issuance backed by hyperscaler guaranteed leases – these are innovations that we have never seen before. These structures have expanded the investor base, reduced the funding frictions, and further blurred traditional boundaries – between both corporate and project finance, and public and private credit markets. At the same time, physical, operational, and political constraints are beginning to shape the pace and the composition of the AI infrastructure build-out – and, by extension, the demand for financing. Grid access, power generation equipment, skilled labor, and permitting delays are emerging as significant constraints. These are compounded by political and regulatory frictions at the local, national, and international level. As power availability becomes a gating factor, the AI build-out is likely to pull energy infrastructure financing more tightly into the orbit of AI infrastructure financing. The clear takeaway is this. The capex requirements underpinning AI infrastructure are expanding exponentially, and with them the role of credit markets in financing this build-out. Along the way, there will be winners and losers, periods of adjustment, and a range of physical, financial, and political constraints that shape outcomes on the margin. But the broader trajectory is certain. The scale, duration, and strategic importance of AI infrastructure investment mean that financing of this will remain a defining theme for credit markets and credit investors for years to come. Thanks for listening. If you enjoy the podcast, please leave us a review wherever you listen and share Thoughts on the Market with a friend or colleague today.

Wie nutzt du KI-Agenten wirklich für dich?

Luca war mal Stefanie. Sie wuchs auf einem Bauernhof im Fricktal auf und musste so manche Hürde überwinden, um heute hier als Luca zu sitzen. Von einer beinahe geplatzter Blase, bis hin zu Selbstmordversuchen, keine einfache Reise. Heute lebt Luca als Mann, als Transmann. Und nein, er ist kein rieeesiger Regenbogenfan. Luca ist einfach froh, hat er den Weg eingeschlagen, der für ihn stimmt. Wie sein Umfeld reagiert hat, welche Hormone und Operationen Luca bereits durch hat und welche noch auf ihn zukommen.. Und wie aus einem Arm, irgendwann hoffentlich ein Penis wird - ihr hört es hier. Und wenn ihr noch mehr über Lucas Reise lesen möchtet - hier sein ganz persönlicher Blog: https://meininneresich.ch Momentan nichts für Luca, aber vielleicht ja für euch. Testet Femtasy: https://links.femtasy.com/DieThronfolge-02062026 einen Monat kostenlos und spare mit dem Code THRON 25 CHF auf dein Jahresabo *Triggerwarnung* von Minute 19:06 bis Minute 29:20 wird das Thema Suizid aufgegriffen.

Studen: Brockenstube Broxi Town komplett abgebrannt; Kallnach: Eiche an Eichenfuhr geht für über CHF 57'000 unter den Hammer

In dieser Folge habe ich Vincent von «freaky finance» zu Gast, der uns zeigt, wie er mit Cash Secured Puts und Covered Calls einen massiven Cashflow aufbaut. Er erklärt ganz transparent seine harten Regeln und warum er nach schmerzhaften Erfahrungen im Corona-Crash konsequent auf Margin verzichtet. Ihr erfahrt zudem, wie Vincent seine Prämienziele festlegt und weshalb US-Aktien oft die beste Wahl für eure ersten Gehversuche mit Optionen sind. Schaut unbedingt rein, wenn ihr eure Dividendenstrategie mit einer cleveren Cashflow-Komponente ergänzen wollt!

Valencia hat sich für 2026 zu viel vorgenommen. Eine totale Sonnenfinsternis im August. Ein Heiliger Gral mit eigenem Jubiläumsjahr. Gay Games, neue Museen, eine Arena, die aussen aussieht wie ein Basketball. Nela Panic war drei Tage dort und hat nachgeschaut, was hinter dem Lärm steckt.Sie erzählt von der gotischen Seidenbörse, deren Säulen wie versteinerte Bäume nach oben wachsen. Vom steinernen Papagei auf dem Mercado Central, der stellvertretend für die Marktfrauen plaudert. Von einem Zoo ohne Gitter und einem Aquarium, in dem Haie über den Köpfen der Besucher schwimmen. Und von der Albufera, wo die echte Paella herkommt – nicht die für Touristen.Am Ende die Frage, die in Valencia keiner mehr stellt: Warum kommen so viele und bleiben einfach? Eine Citytour in drei Tagen, von der Barockfassade bis zur Dachterrasse. Erschienen in der Seazen Sommer-Ausgabe 2026.Die ganze Citytour durch Valencia – mit Karte, Adressen und Bildern – steht in der Seazen Sommer-Ausgabe 2026. Dazu Shanghai, die Costa Verde, Istanbul, Taiwan, Botswana und Cover Artist Channy Chhoeun.→ Jetzt bestellen für 18 € / CHF: seazentravel.com Oder gleich abonnieren und keine Ausgabe mehr verpassen. Hosted on Acast. See acast.com/privacy for more information.

(English below) Florian Teuteberg, Mitgründer und CEO von Digitec Galaxus, empfängt uns im Logistikzentrum in Wohlen und erzählt die ganze Geschichte hinter dem grössten Onlinehändler der Schweiz: von drei Gamern in einem 25-Quadratmeter-Büro bis zu über 3 Milliarden CHF Umsatz.In dieser Swisspreneur Documentary erfährst du:- Wie drei Gaming-Freunde aus Leidenschaft für Hardware ein Milliardenunternehmen aufbauten- Warum der Onlineshop aus der Frustration entstand, Kunden immer das Gleiche erklären zu müssen- Wie Digitec Apple- und Samsung-Produkte grau importierte, nachdem die Hersteller sich weigerten zu liefern- Warum sie ihr gesamtes ERP-System zweimal von Grund auf selbst entwickelten und wie es fast schiefging- Was der Einstieg der Migros verändert hat- Wie sie jetzt in Deutschland und Österreich gegen Amazon antreten---Florian Teuteberg, co-founder and CEO of Digitec Galaxus, welcomes us to the logistics center in Wohlen and tells the full story behind Switzerland's largest online retailer: from three gamers in a 25-square-meter office to over CHF 3 billion in revenue.In this Swisspreneur documentary, you'll learn:- How three gaming friends built a billion-dollar company out of their passion for hardware- Why the online store was born out of frustration at always having to explain the same thing to customers- How Digitec imported Apple and Samsung products through parallel imports after the manufacturers refused to supply them- Why they developed their entire ERP system from scratch twice on their own—and how it almost went wrong- What Migros' entry into the market changed- How they're now competing against Amazon in Germany and AustriaThe cover portrait was edited by ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠www.smartportrait.io⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠.‍Don't forget to give us a follow on⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Instagram⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠,⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Linkedin⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠,⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ TikTok⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠, and⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Youtube ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠so you can always stay up to date with our latest initiatives. That way, there's no excuse for missing out on live shows, weekly giveaways or founders' dinners.

Wie nutzt du KI-Agenten wirklich für dich?

Die meisten Investoren starren 2026 wie das Kaninchen auf die Schlange auf Inflation und Zinsen, während sie den eigentlichen Vermögensaufbau komplett verschlafen. In dieser Folge zeige ich dir, warum nicht das Timing, sondern deine Einstellung und ein klares System über deinen Erfolg an der Börse entscheiden. Ich teile meine Learnings aus über 10 Jahren als Investor und erkläre dir anhand von Studien, warum das Verpassen der besten Börsentage deine Rendite massiv schmälert. Wir räumen gemeinsam mit emotionalen Fehlern wie FOMO und falschem Makro-Fokus auf, damit du endlich langfristig und entspannt ein echtes Vermögen aufbauen kannst.

In dieser Folge spreche ich mit verschiedenen Experten auf der Invest-Messe über ihre krassesten Strategien und wie sie es schaffen, monatlich bis zu 12'000 € zu investieren. Wir beleuchten das gesamte Spektrum von klassischen ETFs über Bitcoin bis hin zu exotischen Sachwerten wie Pokémon-Karten und Lego. Du erfährst aus erster Hand, wie 1'000x-Gewinne mit digitalem Land möglich sind und welche harten Lehren aus Totalverlusten im Kryptomarkt gezogen wurden.

Stoppe das Hamsterrad & baue deine KI:

In dieser Folge erkläre ich, warum die ersten 100.000 Franken der entscheidende Meilenstein beim Vermögensaufbau sind und dass sie vor allem durch eine hohe Sparrate und Disziplin entstehen. Ich zeige, dass Rendite und Zinseszins erst später richtig wirken, während am Anfang hauptsächlich mein Einkommen den Fortschritt bestimmt. Ich empfehle, mit breit diversifizierten ETFs zu starten und langfristig konsequent zu investieren, statt emotional zu handeln oder zu spät anzufangen. Ich betone, dass Zeit mein größter Hebel ist und dass die ersten 100.000 keine Frage des Ob, sondern nur des Wann sind, wenn ich konsequent dranbleibe.

Dans son apéro, JiC nous parle Du match #5 entre les Canadiens et les Sabres Des autres séries dans la LNH Anthony Martineau nous résume la journée du CHFélix Séguin et Patrick Lalime mettent la table pour le match #5 entre les Canadiens et les SabresAntoine Roussel et Maxim Lapierre analysent la série Canadiens - SabresTony Marinaro nous donne son opinion sur l'actualité sportiveDany Dubé est l'invité du segment « Les Coachs »Dave Morissette analyse la série Canadiens - SabresPour de l'information concernant l'utilisation de vos données personnelles - https://omnystudio.com/policies/listener/fr

Stoppe das Hamsterrad & baue deine KI:

Dans son apéro, JiC nous parle Du match #4 entre les Canadiens et les Sabres Des autres séries dans la LNH De Jakub Dobeš De Martin St-Louis Renaud Lavoie nous résume la journée du CHFélix Séguin et Patrick Lalime mettent la table pour le match #4 entre les Canadiens et les SabresAntoine Roussel et Maxim Lapierre analysent la série Canadiens - SabresTony Marinaro nous donne son opinion sur l'actualité sportiveDany Dubé est l'invité du segment « Les Coachs »Philippe Boucher analyse la série Lightning - CanadiensPour de l'information concernant l'utilisation de vos données personnelles - https://omnystudio.com/policies/listener/fr

US President Trump rejected Iran's response to the peace plan, which he called totally unacceptable.Iran's proposal was said to have stressed the need for the US to pay compensation for war damages and emphasised Iran's sovereignty over the Strait of Hormuz. Brent initially climbed above USD 105/bbl but has waned off highs on potential diplomacy.European bourses traded mixed, Compass raised its FY guidance; US equity futures muted.DXY benefited from higher energy prices, CHF underperforms while GBP is cautious as PM Starmer addresses the nation. USTs and Bunds off worst levels as energy benchmarks dip from overnight highs.Looking ahead, highlights include US Existing Home Sales, BoC Market Participants Survey. Supply from the US. Earnings from Hims & Hers, Constellation Energy & Circle Internet.Read the full report covering Equities, Forex, Fixed Income, Commodites and more on Newsquawk

In dieser Folge berichte ich vom Buch Launch Event und erkläre, warum Investieren, Selbstständigkeit und Vermögensaufbau für Menschen aus allen Lebensbereichen relevant sind. Ich teile meine Erfahrungen aus der Community, wo sich Anfänger und Fortgeschrittene austauschen und gemeinsam voneinander lernen.

Dans son apéro, JiC nous parle Du match #2 entre les Canadiens et les Sabres Des autres séries dans la LNH De Martin St-Louis De Jakub Dobeš Anthony Martineau nous résume la journée du CHFélix Séguin et Patrick Lalime mettent la table pour le match #2 entre les Canadiens et les SabresAntoine Roussel et Maxim Lapierre analysent la série Canadiens - SabresTony Marinaro nous donne son opinion sur l'actualité sportiveDany Dubé est l'invité du segment « Les Coachs »On rejoint Étienne Malouin au Casino de MontréalDave Morissette analyse la série Lightning - CanadiensPour de l'information concernant l'utilisation de vos données personnelles - https://omnystudio.com/policies/listener/fr

Stoppe das Hamsterrad & baue deine KI:

"Israeli media: A limited operation against Iran may be carried out to avoid a prolonged war", Al Arabiya reports.Chinese Securities Regulator says that China is to allow qualified foreign investors to trade treasury futures from April 24, 2026, for hedging purposes only.Downbeat sentiment across European bourses, SAP +6% after a EUR 10bln share buyback; NQ outperforms, with INTC +23% post-earnings.FX price action lacklustre, CHF and JPY dodge intervention comments, UoM Final aheadFixed falters as energy climbs, Gilts lag again in catch-up trade and after further hawkish impetus into the BoE.Crude underpinned as eyes remain on US-Iran ceasefire heading into the weekend.Looking ahead, highlights include Canadian Retail Sales (Feb), US UoM Survey Final (Apr), CBR Policy Announcement (Apr).Read the full report covering Equities, Forex, Fixed Income, Commodites and more on Newsquawk

The Consumer Health Forum is calling for the Federal Government to prioritise dental affordability ahead of the budget, off the back of its survey findings that eight in ten are finically strained by dental costs. In this edition of The Conversation Hour we speak with their CEO the sacrifices Australians are having to make to go to the dentist and what measures the CHF would like the Federal Government take to improve equitable access to dental care.Also in this edition, parking inspectors take strike action, why AI might know you better than you think plus a win for road safety.

Das Ergebnis 2025 der RhB-Gruppe erreichte CHF 14.5 Mio. und lag damit erneut deutlich über den Erwartungen. Auch im Kerngeschäft Personenverkehr stieg der Erlös an und bleibe somit das stärkste Segment der RhB und Treiber des aktuellen Erfolgs, erklärt die Unternehmensleitung. Weitere Themen: · Rangerausbildung in Maienfeld schult die Teilnehmenden im Spannungsfeld zwischen Information und Kontrolle. · Das Textilmuseum St.Gallen zeigt eine der grössten BH-Sammlungen der Schweiz.

Weltwoche daily ohne externe Video-Werbung geniessen? Werden Sie Abonnent! Digital nur CHF 9.- im ersten Monat. https://weltwoche.ch/abonnemente/ Aktuelle Ausgabe der Weltwoche: https://weltwoche.ch/aktuelle-ausgabe/ KOSTENLOS: Täglicher Newsletter https://weltwoche.ch/newsletter/ App Weltwoche Schweiz https://tosto.re/weltwoche Die Weltwoche: Das ist die andere Sicht! Unabhängig, kritisch, gut gelaunt. «Schändliche Einmischung»: Brüssels langer Arm nach Ungarn. Massenmigration: SP kontert Strahm. «Europa handlungsunfähig»: US-Starbanker warnt Die Weltwoche auf Social Media: Instagram: https://www.instagram.com/weltwoche/ Twitter: https://twitter.com/Weltwoche TikTok: https://www.tiktok.com/@weltwoche Telegram: https://t.me/Die_Weltwoche Facebook: https://www.facebook.com/DIE.WELTWOCHE

Weltwoche daily ohne externe Video-Werbung geniessen? Werden Sie Abonnent! Digital nur CHF 9.- im ersten Monat. https://weltwoche.ch/abonnemente/ Aktuelle Ausgabe der Weltwoche: https://weltwoche.ch/aktuelle-ausgabe/ KOSTENLOS: Täglicher Newsletter https://weltwoche.ch/newsletter/ App Weltwoche Schweiz https://tosto.re/weltwoche Die Weltwoche: Das ist die andere Sicht! Unabhängig, kritisch, gut gelaunt. Ukraine-Flüchtlinge: Mit dem Flixbus nach Kiew in die Osterferien. Politgaunereien um die EU-Verträge. Kompass-Wietlisbach liest FDP Leviten. Moral-Imperialismus: Bundesbern bestellt Israel-Botschafter ein. Die Weltwoche auf Social Media: Instagram: https://www.instagram.com/weltwoche/ Twitter: https://twitter.com/Weltwoche TikTok: https://www.tiktok.com/@weltwoche Telegram: https://t.me/Die_Weltwoche Facebook: https://www.facebook.com/DIE.WELTWOCHE

Weltwoche daily ohne externe Video-Werbung geniessen? Werden Sie Abonnent! Digital nur CHF 9.- im ersten Monat. https://weltwoche.ch/abonnemente/ Aktuelle Ausgabe der Weltwoche: https://weltwoche.ch/aktuelle-ausgabe/ KOSTENLOS: Täglicher Newsletter https://weltwoche.ch/newsletter/ App Weltwoche Schweiz https://tosto.re/weltwoche Die Weltwoche: Das ist die andere Sicht! Unabhängig, kritisch, gut gelaunt. Meilensteine: Prof. Mörgeli über die Meisterleistung von Hermann Müller, Pionier des Schweizer Weinbaus Die Weltwoche auf Social Media: Instagram: https://www.instagram.com/weltwoche/ Twitter: https://twitter.com/Weltwoche TikTok: https://www.tiktok.com/@weltwoche Telegram: https://t.me/Die_Weltwoche Facebook: https://www.facebook.com/DIE.WELTWOCHE

Hosts: Don Stader, Nate Novotny, Travis Barlock, and Jeffrey Olson In this episode, we reminice about the first 1000 medical minutes presented by EMM and what the next 1000 might hold. Below are all of the episodes referenced in this episode. Please go back and give them all a listen. Segment 1- Recap and Facts 1st medical minute o   April 29, 2016. Almost exactly 10 years ago. o   Diverticulitis and Antibiotics by Dr. Chris Holmes 1000th Medical Minute o   March 30, 2026 o   Treatment of burns by Aaron Lessen o   Edited by Ashley Lyons and published by Jorge Chalit Favorite sub-topics have included: o   Cardiovascular topics- 150 episodes o   Pharmacology- 97 episodes o   Toxicology- 85 episodes o   Neurology- 75 episodes The "Hunting for…" cinematic universe. -Michael Hunt o   399: Hunting for Pancreatitis o   424: Hunting for Measles o   432: Hunting for UTIs o   445: Hunting for the Endotracheal Tube o   455: Hunting for PeeCP o   460: Hunting for PE in Syncope o   487: Hunting for Epiglottitis Obsession with 1966- Chris Holmes o   120: The State of Sepsis in 1966 o   125: Old School CPR - 1966 o   138: Bromide Toxicity - 1966 o   147: GI Bleed - 1966 o   675: CHF like it's 1966 Favorite drug: naloxone/narcan (9) o   7: Heroin Overdose and OTC Narcan o   464: Narcan't? o   516: Narcan and Pulmonary Edema o   931: Naloxone in Cardiac Arrest Favorite disease state: Sepsis (13) o   22: Sepsis Sofa o   219: History of Sepsis o   244: Fever in Sepsis o   263: Early Antibiotics in Sepsis o   272: More on Temperature in Sepsis o   287: Sepsis Bundles o   544: C is for Sepsis Unhinged title combinations o   84: Hypothermia and Lightning Strike: Code Blue o   203: Wine, Milk and… Vaccines!? o   216: Roller Coasters and Kidney Stones o   299: Black Death, Lice, Math, and Pottery o   427: Cookie Dough is Delicious o   670: Operation Tat-Type o   695: Einstein and Cellophane o   777: Grass, weed and ancient Rome o   781: Foxglove, dropsy, and Salvador Dali o   959: The KLM Flight Disaster and Lessons in Healthcare Communication Most frequent contributors -          Aaron Lessen- 192 -          Don Stader- 84 -          Jarod Scott- 83 -          Peter Bakes- 53 -          Samuel Killian- 45 -          Dylan Luyten- 41 -          Erik Verzemnieks- Dozens -          Michael Hunt- 34 -          Travis Barlock- 30 -          Ricky Dhaliwal- 25 Top female voices o   Rachael Duncan, PharmD o   Rachel Beham, PharmD o   Meghan Hurley o   Gretchen Hinson o   Suzanne Chilton o   Katie Sprinkle Most listened to -          8. Podcast 835: Syncope Review -          7. Podcast 766: Truth about Tramadol -          6. Podcast 839: Causes of Pancreatitis -          5. Podcast 760: Why Fentanyl is the Worst -          4. Podcast 844: Dental Infections -          3. Podcast 846: Early Repolarization vs. Anterior STEMI -          2. Podcast 845: Hyperkalemic Cardiac Arrest -          1. Podcast 847: ECMO CPR Mini-game: who has actually seen our most rare diagnoses? o   18: Lemierre's Syndrome – Septic thrombophlebitis of the internal jugular vein after oropharyngeal infection leading to septic emboli. o   139: Locked-in Syndrome – Ventral pontine lesion causing quadriplegia and inability to speak with preserved consciousness and eye movements. o   144: Moyamoya Disease – Progressive stenosis of intracranial carotids with development of fragile collateral vessels causing strokes. o   221: Cotard Delusion (Walking Corpse Syndrome) – Psychiatric disorder where patients believe they are dead or do not exist. o   240: Pott's Puffy Tumor – Frontal bone osteomyelitis with subperiosteal abscess from sinusitis causing forehead swelling. o   277: Mucormycosis (Rhizopus) – Angioinvasive fungal infection in immunocompromised patients causing rapid tissue necrosis. o   293: Transient Global Amnesia – Sudden, transient loss of ability to form new memories that resolves within 24 hours. o   329: Hypokalemic Periodic Paralysis – Episodic muscle weakness due to intracellular potassium shifts. o   374: Iliac Artery Endofibrosis – Exercise-induced fibrosis of the iliac artery causing claudication in athletes. o   466: Subacute Sclerosing Panencephalitis (SSPE) – Progressive, fatal neurodegenerative disease from persistent measles infection. o   477: Postpolypectomy Electrocoagulation Syndrome – Transmural burn of the colon after polypectomy causing localized peritonitis without perforation. o   578: Brown-Séquard Syndrome – Hemisection of the spinal cord causing ipsilateral motor/proprioception loss and contralateral pain/temperature loss. o   697: Kounis Syndrome – Acute coronary syndrome triggered by allergic reaction causing coronary vasospasm or plaque rupture. o   973: Meningitis Retention Syndrome – Acute urinary retention due to sacral nerve dysfunction during meningitis. Segment 2- Individual Interviews Segment 3- Looking forward Segment 4- Trivia Podcast 38, what is significant about diphtheria and March 18th? o   On March 18th, the Iditarod is run in Alaska to commemorate a sled dog team, led by Balto, that ran from Nome to Anchorage and back to provide children in Nome with the diphtheria anti-toxin serum. Podcast 52: Syphilis the Great Imitator. The study of Syphilis or "Syphilology" evolved into the field of what? o   Dermatology Podcast 121:  The Poor Man's Methadone. What is the poor man's methadone? o   Imodium Podcast 136:  James Lind, conducted the first clinical trial in 1747 and proved that what cure what? Hint: think vitamins. o   Citrus fruits cure scurvy. Podcast #213: --- and Potatoes. What food has been shown to lower LDL? o   Oats Podcast #216: Roller Coasters and Kidney Stones. A study used a model of a kidney and ureter with different sized stones and put it on ------ roller coaster in Disney World. o   Thunder Mountain Podcast #261. ---- was introduced to treat ACE-inhibitor induced angioendema. but later, better-powered studies showed that it had no benefit compared to standard treatment. o   Icatibant Podcast #304: ---. ---- was a formal medical diagnosis, and one that dates back to 17th century when soldiers had longing for home and melancholy with a constellation of symptoms including lethargy, sadness, disturbed sleep, heart palpitations, GI complaints, and/or skin findings for which the only cure was to return home. o   Nostalgia Podcast # 351: Steakhouse Syndrome. What is steakhouse syndrome? o   Impacted food bolus 2/2 esophageal stricture Podcast # 362: Giant Hogweed. What can Giant Hogweed cause. o   Photosensitivity, severe blisters, and burns Podcast #398:  Who is gonna fail your antibiotic plan? What vital sign abnormality at triage had the highest odds ratio for treatment failure for the treatment of cellulitis with antibiotics. o   Tachypnea Podcast # 458: A Tylenol a Day Keeps the ---- Away? A recent study investigated the effect of scheduled IV acetaminophen on the incidence of ---- in post-CABG patients in the ICU o   Delerium Podcast 554: Sleeping Away Alzheimer's. What is the difference between white noise and pink noise? o   White noise is all the surrounding sound frequencies mixed together that your brain tunes down so you don't get distracted while you're sleeping o   Pink noise, or deep soothing noises, is the accentuated bass sounds like falling rain or waves crashing your brain keys into while sleeping. o   Pink noise during sleep has been shown to increase stage 4, creating more CSF washout of beta amyloid. Podcast 580:  Origin of PPE. Why were rubber gloves invented? o   The invention of surgical gloves are credited to surgeon William Halsted. He developed gloves because one of his assistants (and later wife), Carol Hampton, was having severe irritation due to a caustic pre-op disinfecting process. They developed the rubber glove for Hampton which garnered popularity, and by the early 20th century, half of surgeons were using rubber gloves. Podcast 587:  Puppies Preventing Burnout? Puppies lower stress, what activity in that study increased stress? o   Coloring, because they were denied a chance to play with a puppy Podcast 596: Weather Can be a Headache. What are the three weather events that can increase the frequency of headaches? o   High temp o   Low humidity o   High air pollution Podcast 612: Origin of Vaccines. Guess both diseases. The potential of vaccinations was first observed in the late 1600s when Jenner observed people who had cowpox never contracted ----. Years later, Louis Pasteur inoculated chickens with ---- after his assistant accidently created the first live attenuated vaccine by creating a weakened bacteria when he left the bacteria out while he went on vacation o   Smallpox, cholera Podcast 670: Operation Tat-Type. In 1951, Operation Tat-Type began tattooing adults with their ---- in an effort to prepare for ---- in the time of the Cold War and the Korean War o   Blood type, rapid transfusions Podcast 695: Einstein and Cellophane. Albert Einstein had ----- as a middle-aged man. Dr. Rudolph Nissen, founder of the Nissen fundoplication, performed exploratory surgery for this pain and found a ---- -          The only treatment for an AAA at that time was to----, causing a fibrotic response to prevent rupture -          Einstein died 7 years after this surgery, likely from his leaking abdominal aortic aneurysm o   chronic abdominal pain o   AAA o   wrap the vessel in cellophane Podcast 748: -----. Whale blubber, honey, home fermented foods, homemade wine (especially the wine made in prison), and improperly stored canned food can all contain the toxin o   Botulism Podcast 777: Grass, Weed, and Ancient Rome. Wine and wormwood and white hellborn were used in ancient rome to treat ----. o   Nausea, sea sickness Podcast 821: EKGs in Syncope. Travis suggests a mnemonic for remembering additional EKG findings to look for in syncope o   WOBBLER §  Wolff-Parkinson-White (WPW) §  Obstructed AV node §  Brugada syndrome §  Bifascicular block §  Left Ventricular Hypertrophy (LVH) §  Epsilon waves §  Repolarization abnormalities Podcast 890: Outdoor Cold Air for Croup A 2023 study, published in the Journal of Pediatrics, investigated whether a 30-minute exposure to outdoor cold air could improve mild to moderate croup symptoms before the onset of steroid effects. In what country was this study conducted. o   Switzerland Podcast 925: Pediatric Tongue Entrapment. Case study of a peds patient with his/her tongue stuck in a drinking cap. What was the substance that finally set it free? o   Table sugar Podcast 960: Frank's Sign - A Marker for Coronary Artery Disease. What is Frank's Sign? o   Bilateral earlobe crease Thank you to all that make the EMM awesome! Hosted and editted by Jeffrey Olson MS4 | Additional editting by Jorge Chalit, OMS4 Donate: https://emergencymedicalminute.org/donate/ Join our mailing list: http://eepurl.com/c9ouHf

US President Trump said in his primetime address that the mission in Iran will be finished very fast and the US will hit Iran very hard over the next 2–3 weeks.Trump warned that the US will strike Iran's electric plants if there is no deal and could also target its oil facilities.Energy surges as Brent nears USD 110/bbl; metals slump.Equities fall as Trump reignites tension with Iran, BAYN GY subject to potential 100% levy.DXY regains the 100 handle, CHF little-moved following inflation print.Fixed income under pressure as benchmarks continue to be driven by energy prices.Looking ahead, highlights include US Challenger Job Cuts (Mar), Initial Jobless Claims (Mar/28), Trade Balance (Feb), Canadian Trade Balance (Feb). Speakers include Fed's Logan & Bowman. Read the full report covering Equities, Forex, Fixed Income, Commodites and more on Newsquawk

Revolution des DenWeltwoche daily ohne externe Video-Werbung geniessen? Werden Sie Abonnent! Digital nur CHF 9.- im ersten Monat. https://weltwoche.ch/abonnemente/ Aktuelle Ausgabe der Weltwoche: https://weltwoche.ch/aktuelle-ausgabe/ KOSTENLOS: Täglicher Newsletter https://weltwoche.ch/newsletter/ App Weltwoche Schweiz https://tosto.re/weltwoche Die Weltwoche: Das ist die andere Sicht! Unabhängig, kritisch, gut gelaunt. Revolution des Denkens, Urknall der Freiheit: Ostern – Bedeutung, Relevanz, Sprengkraft, Aktualität. Die Weltwoche auf Social Media: Instagram: https://www.instagram.com/weltwoche/ Twitter: https://twitter.com/Weltwoche TikTok: https://www.tiktok.com/@weltwoche Telegram: https://t.me/Die_Weltwoche Facebook: https://www.facebook.com/DIE.WELTWOCHEkens, Urknall der Freiheit: Ostern – Bedeutung, Relevanz, Sprengkraft, Aktualität.

Weltwoche daily ohne externe Video-Werbung geniessen? Werden Sie Abonnent! Digital nur CHF 9.- im ersten Monat. https://weltwoche.ch/abonnemente/ Aktuelle Ausgabe der Weltwoche: https://weltwoche.ch/aktuelle-ausgabe/ KOSTENLOS: Täglicher Newsletter https://weltwoche.ch/newsletter/ App Weltwoche Schweiz https://tosto.re/weltwoche Die Weltwoche: Das ist die andere Sicht! Unabhängig, kritisch, gut gelaunt. Nato-Professor Cottier: Schweizer Neutralität muss weg. EU-Unterwerfung: Wie viel Kantönligeist steckt noch in der Schweiz? Überempfindlich: Keller-Sutter klagt gegen Elon Musk. Bundesrat gegen Atomverbots-Initiative. Frohe Ostern mit der neuen Weltwoche! Die Weltwoche auf Social Media: Instagram: https://www.instagram.com/weltwoche/ Twitter: https://twitter.com/Weltwoche TikTok: https://www.tiktok.com/@weltwoche Telegram: https://t.me/Die_Weltwoche Facebook: https://www.facebook.com/DIE.WELTWOCHE

Weltwoche daily ohne externe Video-Werbung geniessen? Werden Sie Abonnent! Digital nur CHF 9.- im ersten Monat. https://weltwoche.ch/abonnemente/ Aktuelle Ausgabe der Weltwoche: https://weltwoche.ch/aktuelle-ausgabe/ KOSTENLOS: Täglicher Newsletter https://weltwoche.ch/newsletter/ App Weltwoche Schweiz https://tosto.re/weltwoche Die Weltwoche: Das ist die andere Sicht! Unabhängig, kritisch, gut gelaunt. Spitäler als Todesfabriken? Hürden für Sterbehilfe sinken. Bahnfahren wird teurer. Dubais Reiche liebäugeln mit der Schweiz. SVP auf Siegeskurs: Was die FDP lernen kann. Israel: Todesstrafe für Terroristen. Die Weltwoche auf Social Media: Instagram: https://www.instagram.com/weltwoche/ Twitter: https://twitter.com/Weltwoche TikTok: https://www.tiktok.com/@weltwoche Telegram: https://t.me/Die_Weltwoche Facebook: https://www.facebook.com/DIE.WELTWOCHE

Weltwoche daily ohne externe Video-Werbung geniessen? Werden Sie Abonnent! Digital nur CHF 9.- im ersten Monat. https://weltwoche.ch/abonnemente/ Aktuelle Ausgabe der Weltwoche: https://weltwoche.ch/aktuelle-ausgabe/ KOSTENLOS: Täglicher Newsletter https://weltwoche.ch/newsletter/ App Weltwoche Schweiz https://tosto.re/weltwoche Die Weltwoche: Das ist die andere Sicht! Unabhängig, kritisch, gut gelaunt. Berner Beben: SVP legt massiv zu. Iran-Krieg: Die Schweiz hat die Neutralität verlernt. Dunkle Wirtschaftsaussichten, was Bern jetzt tun muss. Keine Sorgen, bald ist Ostern Die Weltwoche auf Social Media: Instagram: https://www.instagram.com/weltwoche/ Twitter: https://twitter.com/Weltwoche TikTok: https://www.tiktok.com/@weltwoche Telegram: https://t.me/Die_Weltwoche Facebook: https://www.facebook.com/DIE.WELTWOCHE

Weltwoche daily ohne externe Video-Werbung geniessen? Werden Sie Abonnent! Digital nur CHF 9.- im ersten Monat. https://weltwoche.ch/abonnemente/Aktuelle Ausgabe der Weltwoche: https://weltwoche.ch/aktuelle-ausgabe/KOSTENLOS:Täglicher Newsletter https://weltwoche.ch/newsletter/App Weltwoche Schweiz https://tosto.re/weltwocheDie Weltwoche: Das ist die andere Sicht! Unabhängig, kritisch, gut gelaunt.SVP-Grossaufmarsch gegen «10-Millionen-Schweiz». Parlamentarischer Widerstand gegen «EU-Unterwerfung». Iran-Eskalation und Asylstopp. Nidwalden prescht bei Sterbehilfe vorDie Weltwoche auf Social Media:Instagram: https://www.instagram.com/weltwoche/Twitter: https://twitter.com/WeltwocheTikTok: https://www.tiktok.com/@weltwocheTelegram: https://t.me/Die_WeltwocheFacebook: https://www.facebook.com/DIE.WELTWOCHE Hosted on Acast. See acast.com/privacy for more information.

Weltwoche daily ohne externe Video-Werbung geniessen? Werden Sie Abonnent! Digital nur CHF 9.- im ersten Monat. https://weltwoche.ch/abonnemente/Aktuelle Ausgabe der Weltwoche: https://weltwoche.ch/aktuelle-ausgabe/KOSTENLOS: Täglicher Newsletter https://weltwoche.ch/newsletter/App Weltwoche Schweiz https://tosto.re/weltwocheDie Weltwoche: Das ist die andere Sicht! Unabhängig, kritisch, gut gelaunt.Meilensteine der Schweizer Geschichte: Prof. Christoph Mörgeli über das Schloss Frauenfeld und den unterschätzten Kanton ThurgauDie Weltwoche auf Social Media:Instagram: https://www.instagram.com/weltwoche/Twitter: https://twitter.com/WeltwocheTikTok: https://www.tiktok.com/@weltwocheTelegram: https://t.me/Die_Weltwoche Facebook: https://www.facebook.com/DIE.WELTWOCHE Hosted on Acast. See acast.com/privacy for more information.

Weltwoche daily ohne externe Video-Werbung geniessen? Werden Sie Abonnent! Digital nur CHF 9.- im ersten Monat. https://weltwoche.ch/abonnemente/Aktuelle Ausgabe der Weltwoche: https://weltwoche.ch/aktuelle-ausgabe/KOSTENLOS:Täglicher Newsletter https://weltwoche.ch/newsletter/App Weltwoche Schweiz https://tosto.re/weltwocheDie Weltwoche: Das ist die andere Sicht! Unabhängig, kritisch, gut gelaunt.Armeechef Roos: Voll auf EU- und Nato-Kurs, keine Ahnung vonNeutralität.Staatlich geförderte NZZ: 341.250 Franken Abo-Subventionenvom Bund.Wehrminister Pfister streckt Nato-Fühler nach Polen aus.400.000 Franken für Flüchtlingsfamilie in Wattwil? Interessenkonfliktbeim grünen Zürcher Stadtrat LeupiDie Weltwoche auf Social Media:Instagram: https://www.instagram.com/weltwoche/Twitter: https://twitter.com/WeltwocheTikTok: https://www.tiktok.com/@weltwocheTelegram: https://t.me/Die_WeltwocheFacebook: https://www.facebook.com/DIE.WELTWOCHE Hosted on Acast. See acast.com/privacy for more information.

Respiratory crises in the field rarely fit textbook categories. JEMS Development Editor Mike Brown talks with Hamilton Medical's Jesse Carroll to separate Type 1 (hypoxemic) from Type 2 (hypercapnic) respiratory failure and recognize the mixed presentations clinicians actually see. They walk through practical cues (SpO2 trends vs end‑tidal CO2), common causes (CHF, COPD, obesity, neuromuscular weakness), and epidemiology: roughly 360,000 prehospital respiratory calls annually with 41% involving COPD and obesity rates rising from 32% to about 60% since 1988. Jesse explains why pressure, flow and volume, not oxygen alone, drive meaningful physiologic change, how device limitations (disposable CPAP, pneumatic and turbine systems) affect flow delivery, and when early noninvasive strategies can buy time or prevent intubation.

Timestamps: 10:22 - Navigating the Shift from Academia to Startup16:47 - Innovative Skin Tissue Therapy: The NovoSkin Product33:53 - Navigating Growth Challenges41:37 - Investment Journey and StrategiesThis episode is part of the Swisspreneur Scale-up Circle content, our curated community of Swiss Series A + founders and operators where you can get operator grade insight. Episode Summary:Daniela Marino is the co-founder and CEO of Cutiss, a Swiss late-stage tech bio company developing personalized skin tissue therapies for reconstructive surgery. With a background in biotechnology and years in academia, Daniela transitioned from research into entrepreneurship to bring a breakthrough innovation to patients. Today, Cutiss is advancing through clinical trials, working to turn regenerative science into real-world medical impact.In this episode, Daniela shares why cutting-edge scientific research often struggles to become companies, what it takes to transition from academia into building a startup, and how Cutiss scaled into a late-stage tech bio through an unconventional path - raising over CHF 100 million without relying on traditional venture capital. Daniela also shares insights on navigating the European regulatory landscape and why Switzerland can be a unique advantage for deep tech founders.Beyond the business, Daniela reflects on the personal reality of becoming a founder without prior startup experience, including learning the fundamentals while building the company in real time. She talks about the importance of resilience, surrounding yourself with the right people, and leading a growing team through uncertainty. The conversation also touches on the real-world impact of Cutiss' work - including supporting patients with severe burns, such as victims of the recent Crans-Montana tragedy - and what it means to build a company with a deeply human mission.The cover portrait was edited by ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠www.smartportrait.io⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠.‍Don't forget to give us a follow on⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Instagram⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠,⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Linkedin⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠,⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ TikTok⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠, and⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Youtube ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠so you can always stay up to date with our latest initiatives. That way, there's no excuse for missing out on live shows, weekly giveaways or founders' dinners.

Israel attempted to assassinate Iran's Intelligence Minister Khatib overnight, Jerusalem Post reported, citing an Israeli official, but is still awaiting the results of the target. Iran's Foreign Minister said Iran will target US forces wherever they assemble, including near urban areas. Iran fired retaliatory missiles towards Tel Aviv for the killing of Larijani.European equities gain, Banks benefiting from a delay in capital requirements; US equity futures follow peers.Mostly flat FX trade heading into the FOMC; CHF narrowly lags ahead of tomorrow's SNB.Crude continues to dictate macro sentiment; Gold rotates around USD 5,000/oz.Fixed income firmer amid energy downside ahead of key central bank announcements.Looking ahead, highlights include US PPI (Feb), New Zealand GDP (Q4), BoC, Fed & BCB Policy Announcements. Speakers include BoC's Macklem & Rogers, Fed Chair Powell & NVIDIA (NVDA) CEO Huang. Earnings from Micron.Read the full report covering Equities, Forex, Fixed Income, Commodites and more on Newsquawk

This week on The Business of Watches, we're in La Chaux-de-Fonds to talk to the man heading Greubel Forsey, one of the most revered and respected brands in independent watchmaking. The company had been on a recent roll, with Meta CEO and chairman Mark Zuckerberg seen wearing its pricey timepieces and a 'Mechanical Exception' win for its Nano Foudroyante at the Grand Prix d'Horlogerie Genève (a watch also in Zuckerberg's collection). Then news broke that Stephen Forsey, one of the brand's founders, was stepping down from the board, and, in a widely-seen social media post, Forsey said he had been "disengaged" from his duties by the board and chose to resign.  Nydegger tells us some of the backstory to the situation and how the company plans to move forward under stable ownership. Greubel Forsey isn't looking for investors, and should Forsey want to sell his minority stake, Robert Greubel, his fellow co-founder and majority owner, has a right of first refusal on the shares. So where is Greubel Forsey headed? Nydegger says the only thing shrinking will be the size of its timepieces as it continues a push to make its watches more wearable and possibly prices as they are trying to produce an entry-level watch in the lineup priced at around CHF 120,000 or less. They haven't quite got there just yet.  But first, we're joined by Arthur Touchot, the co-founder of Marteau & Co., to talk about his upstart auction house's plans to cut independent watchmakers in on the sale proceeds. For its sophomore edition, called 'The Echo', Marteau is auctioning off watches from independents, including Simon Brette, a Berneron Mirage Tiger Eye, vintage Daniel Roth, and an Audemars Piguet Starwheel. So will mighty AP be in line for 3% of the hammer price? Tune in to find out. Show Notes 1:30 Arthur Touchot  2:40 Marteau & Co.  4:13 New Swiss Auctioneer Aims To Bring 'Artist's Resale Right' Concept To Independent Watchmaker Sales  6:21  The Echo catalogue (Marteau & Co.)  11:40 M.A.D. Gallery Geneva  12:52 AHCI  14:11 Audemars Piguet Starwheel (Hodinkee)  16:08 Greubel Forsey (The Art of Invention)  19:14 Greubel Forsey Gets New CEO - Michel Nydegger (SJX)  20:20 Introducing The Greubel Forsey Double Tourbillon Technique Black, The First Titanium Watch From Greubel Forsey  20:40 Guy Takes $600,000 Greubel Forsey Double Tourbillon 30 Degrees Technique Swimming, Resists Heart Attack (Hodinkee)  24:02 Quadruple Tourbillon The History  24:50 Interview: Giulio Papi, Director Audemars Piguet Renaud & Papi (Hodinkee)  29:59 Greubel Forsey Watches: A Division of Labor (NYT paywall)  32:01 Micro-machinist in watchmaking (FHH)  38:20 These Watches Used To Be A Secret Of The Ultra Rich. Not Anymore. (Bloomberg paywall)  46:30 Stephen Forsey, Co-Founder Of Greubel Forsey, Steps Down From Company Board (Hodinkee)  49:02 Michel Nydegger acceptance speech GPHG 2025 Mechanical Exception prize (GPHG Youtube)  54:40 Mark Zuckerberg Wears $900,000 Watch To Announce End Of Meta Fact Checks (Bloomberg paywall)  55:30 Greubel Forsey Family 

This week on The Business of Watches, we talk to the man who runs the brand that makes the mighty El Primero movement. Benoit de Clerck has been in the CEO chair at Zenith Watches for a couple of years now, and that's coincided with a challenging time for the sector and one of the industry's most storied brands, with more than 160 years of history and still located in its original manufacturing location in Le Locle, Switzerland.  Under de Clerck's leadership, Zenith is responding to the challenges with a multi-pronged approach. It's throttling production to keep sell-in and sell-out balanced, he says. But it's also stepping up its movement, making production expertise and supplying more calibers to other brands, also under the LVMH watch group umbrella. As for those reports and rumors that Zenith is up for sale? We ask de Clerck straight up if the El Primero maker is on the selling block. Have a listen to hear his forceful and fulsome response.  But first, former Hodinkee editor Logan Baker drops in to give his take on Zenith, as well as reports that the valuation of Breitling has been reduced by its private equity ownership. Logan also has a few of his unique vintage Zenith watches on hand for us to check out.  Show Notes  1:30 Logan Baker (Hodinkee)  1:40 A Watch Enthusiast's Guide to Geneva (Logan Baker, Phillips)  2:34 Zenith Manufacture Le Locle  5:13 Zenith Chronometer Calatrava Circa 1964  6:50 Square case Zenith Defy with integrated bracelet  7:34 Zenith Elite Movement  9:45 Morgan Stanley Swiss Watcher Report  10:50 Private equity owners slash valuation of Swiss watchmaker Breitling (FT paywall)  13:15 Zenith Celebrates Its 160th Anniversary With CEO Benoit de Clerck (YouTube, Watch Adviser)  15:25 Hands-On: Zenith's Resurrected Caliber 135-Powered 'G.F.J.' (Hodinkee)  15:49 Hands-On: The Zenith Chronomaster Original Triple Calendar Lapis Lazuli (Hodinkee)  17:01 GPHG Chronometry Prize 2025  18:40 I Spend All Day Researching Vintage Zenith Watches – Here's Why This El Primero Is So Important To Me  20:03 Introducing: Zenith Defy Chronograph USM (Hands-On And Live Pics)  26:03 LVMH response to report Zenith brand is up for sale (Hodinkee story on Baume & Mercier sale) 27:30 Tiffany's New Watch Courts The Male Buyer (New York Times)  32:07 Hublot Big Bang With Zenith Movement (Monochrome)  37:01 Zenith: The Heart of Watchmaking (YouTube)  39:05 Zenith A Visit To The Manufacture  41:02 Zenith GFJ  42:32 CHF x USD (Yahoo)

US President Trump said the US continues to carry out large-scale combat operations in Iran, while he added that Iran could have missiles capable of reaching America soon and had refused to cease its pursuit of nuclear weapons.US and China trade negotiators are to meet mid-March prior to the Trump-Xi summit, with Treasury Secretary Bessent and Chinese Vice Premier He Lifeng expected to convene in Paris at the end of next week to discuss bilateral matters.European bourses remain under pressure, Utilities hit further as QatarEnergy halts production; US equity futures reverse Monday's gains.DXY continues its war-related ascent, CHF underperforms, GBP lags into the Spring Statement.Fixed income falters as energy soars, causing heightened inflation risks.Crude prices continue to climb as the Iranian war enters day four; Precious metals slip. Looking ahead, highlights include US RCM/TIPP (Mar), New Zealand Export/Import Prices, Australian Composite PMI Final (Feb). Speakers include Fed's Williams & Kashkari, UK Spring Statement. Earnings from CrowdStrike, Best Buy, Target, AutoZone, Bayer, Adidas, & Continental.Read the full report covering Equities, Forex, Fixed Income, Commodites and more on Newsquawk

This week on The Business of Watches, we go behind the scenes with the man who compiles and crunches the numbers for the Morgan Stanley Swiss Watcher report, the most influential and widely read annual financial league table on the industry. Oliver Müller has been around the sector for some three decades, beginning his career at Omega before executive roles at a series of brands, including Laurent Ferrier, where he served as Chief Executive Officer. He's now a consultant to the industry and has helped shape brand strategy and positioning for the likes of Akrivia and Rexhep Rexhepi, among others.  Müller's most high-profile gig these days is compiling the estimates of Swiss brand revenue and volumes for the Morgan Stanley report. It's the top league table for the sector, and he tells us how he calculates and decides on the estimates that get published. Not everyone is a fan. Swatch Group has long criticized the report, now in its 9th edition, and Müller tells us why he believes Swatch and its leadership don't always appreciate the numbers. But first, Hodinkee founder Ben Clymer drops in for his Business of Watches debut. Ben tells us about his recent trip to Geneva and what he's hearing from some of the big brand executives. He also gives us his take on some of the data deep inside the Morgan Stanley report.  Show Notes  1:30 Ben Clymer (Hodinkee)  2:11 Watches of Switzerland Group 4:10 Gold price 4:42 USDxCHF 6:40 Audemars Piguet CEO Ilaria Resta Drives Double-Digit Sales Increase For Brand's 150th Anniversary Year 10:20 Cartier Santos de Cartier in Titanium (And Steel) — The Watches You Want From Cartier, Whether You Know It Or Not (Hodinkee) 12:55 Cartier's NSO – Or "New Special Order" –  Watch Program Is Over, At Least As We Know It (Hodinkee) 15:00 LuxeConsult (Oliver Müller) 15:15 Morgan Stanley 18:15 Richard Mille 18:34 Bucherer 24:13 When Banks Try To Unlock The Watchmaking Secret (Le Temps) (In French) 32:47 F.P. Journe  32:50 H. Moser & Cie. 37:30 MB&F 39:20 Raymond Weil 39:25 Frederique Constant 39:30 Christopher Ward 43:05 Jacob & Co. 44:00 How The Five Time Zone Shaped Modern Watch Culture (Hodinkee Malaika Crawford) 49:20 Tudor sales slump by 23% but Rolex turnover ticks up 5% to CHF 10.6 billion (Watchpro) 53:20 IWC 54:15  Jaeger-LeCoultre 59:20 Richemont Sells Baume & Mercier 1:01:30 Swatch Group Brands 1:06:20 Rolex careers and work locations including Biel / Bienne 

Hannah speaks with Fook Hien about recent US equity underperformance relative to global peers and what factors are expected to support a catch-up US equity rally. They also discuss thoughts on other currencies like the GBP and CHF.You can read our latest Weekly Market View today here.Speakers: Hannah Chew, Portfolio Strategist, Standard Chartered Bank Yap Fook Hien, Senior Investment Strategist, Standard Chartered Bank For more of our latest market insights, visit Market views on-the-go or subscribe to Standard Chartered Wealth Insights on YouTube.

What's in a name? More specifically, what is a name worth? Gerald Genta, likely the most famous watch designer in history and responsible for conjuring iconic models from the Audemars Piguet Royal Oak, the Patek Philippe Nautilus, the IWC Ingenieur, and the Universal Geneve Polerouter, among others, sold his eponymous watch brand and name to what is now Bulgari and LVMH in the early 2000s. Then he started another brand - using his middle name instead of his family name - and that became Gerald Charles. It was sold to the Ziviani family in Italy in 2003, as Genta remained employed at the company as chief designer until his death in 2011. The brand continued producing mostly one-off, bespoke pieces on a small scale for wealthy clients until 2019, when Federico Ziviani, then in his early 20s, took over as Chief Executive Officer and pushed the Gerald Charles brand to a new phase. That would see it draw on designs from Genta's era with the company, most specifically the 'Maestro' case, and sell watches to consumers, first online and then through retailers. Production has climbed from about 200 watches a year to more than 1,500, and prices have climbed as well, to an average of about CHF 27,000, Ziviani tells us in an interview recorded at the company's operations in Geneva, where it has an atelier and a small museum that traces the history of the brand and its production. Ziviani is enthusiastic and passionate about the family-owned company that is now sold in about 100 retail stores globally. And he makes the case for why he thinks Gerald Charles watches deserve their hefty price tag. But first, we jump into some of the recent business headlines in the watch world. Rolex has consolidated its position as the dominant Swiss brand for watches priced above CHF 3,000 francs with more than 60% market share by sales, according to Swiss bank Vontobel. The bank also ranks the top brands by estimated sales, and we consider the list. And the Contrôle Officiel Suisse des Chronomètres, or COSC, is launching a new higher-tier standard to test the accuracy and precision of Swiss watches. We discuss what that might mean for the Swiss industry, brands, and customers. Show Notes 1:40 Rolex Trimmed Production In 2025 According To Swiss Bank Vontobel 7:06 Gold price (Yahoo) 7:30 Switzerland's COSC Unveils 'Excellence Chronometer' Level Of Certification 14:20 Gerald Charles 15:00 Gerald Genta (Wikipedia)  15:49 Gerald Genta Gefica Safari (Europa Star) 17:11 Audemars Piguet Italia (Bloomberg) 18:20 Giampaolo Ziviani and Gerald Genta (Instagram) 26:20 Gerald Charles website 27:30 Ticino, Switzerland (Wikipedia) 38:30 Gerald Charles Ambassadors 42:15 Swiss Made or Swiss Charade? (ScrewDownCrown) 45:00 Gerald Genta (LVMH) 46:30 Gerald Charles History48:00 USD x Swiss Franc (Yahoo) 

Welcome to another episode of Fratello On Air. This week, we hop into our time machine and travel back 10 years to 2016. As we'll see, in some ways, this wasn't so long ago. Yet, in others, it was a different lifetime. Join us as we look back on fonder days.HandgelenkskontrolleIt's been a while since we've recorded, and much of this is down to Mike's travels in Germany. Sadly, on one of the trips, he had a very Balazs-like travel experience involving planes and trains. If he did have a time machine, he'd probably go back and choose to sleep through his alarm that day. We mention an upcoming Sotheby's auction featuring a pair of Michael Jordan's shoes from the Dream Team Barcelona Olympics. Balazs discusses the return of The Night Manager, a show that, coincidentally, has returned after its first season in 2016! For the Handgelenkskontrolle, Balazs is wearing an upcoming release, the Nivada Grenchen F77 MKII. Mike was wearing his Rolex Sea-Dweller 1665 "Great White" in Germany and still has it on his wrist.Taking our time machine back to 2016Yes, it's hard to believe that 2016 was 10 years ago! Time flies! In this episode, we're reminiscing about a year that brought some interesting releases and behavior. Specifically, vintage watches were within a boom period. In particular, a Patek Philippe 1518 sold at Phillips for over CHF 11 million! It was hard for us to believe that watches were achieving these sums a decade ago.Many new watches from back then still feel relatively modern, but there's no doubt that larger diameters and chunkier cases were in vogue. The Blancpain Bathyscaphe Blue and Ceramic is a good example of this, but to be fair, the same basic platform is still in the catalog today. Speaking of big and robust watches, Robert-Jan reviewed the Sinn U212, which still looks fresh. If we truly want to feel old, Tudor was already in its second year of offering non-ETA movements. Omega launched a rare box-office stinker with the blue and white CK2998, a piece that has aged quite well.Our time machine continues its journey and finds the wild Hublot Big Bang Berluti, which was available in gold or steel and showed off a leather dial. Seiko, announced a partnership with PADI. This caused a stir, and several of us on the team grabbed one of the new models. TAG Heuer announced a Monza PVD, a retro chronograph with a thick case. However, we save the most significant announcement for last. Rolex, after producing steel Daytona 116500LN models with a steel bezel for over 25 years, introduced pieces with ceramic bezels. Understandably, the excitement was palpable and hit Basel like a hurricane. We remark that these watches have been unavailable since that time!We hope you enjoy today's episode. Share your watch memories from 2016 in the comments below, and let us know if we forgot any momentous pieces.

Kiera is joined by the tooth-healer himself, Jason Dent! Jason has an extensive background in pharmacy, and shares with Kiera where his pharmaceutical experience has bled over into dentistry. This includes the difference between anti-quag and anti-platelet and which medications are probably safe, what to do to shorten the drag time in the pharmacy, how to write prescriptions most efficiently, and more. Episode resources: Subscribe to The Dental A-Team podcast Schedule a Practice Assessment Leave us a review Transcript: The Dental A Team (00:00) Hello, Dental A Team listeners. This is Kiera and today is a really awesome and unique day. It is, think the second time I've had somebody in the podcast studio with me live for a podcast and it's the one and only Jason Dent. Jason, how are you? I'm doing well. Good morning. Thanks for having me. It is crazy. I I watch Instagram real like this all the time where people are like in the podcast and they're hanging out on two chairs and couches and now look at us. We're doing it. Cheers. Cheers.   That was a mic cheer for those of you who are only listening, but yeah, Jace, how does this feel to be on the podcast? It's weird. Like I was not nervous at all talking about it. I got really nervous as soon as you hit play. So if I stumble over my words, please forgive me ahead of time. Well, Jason, I appreciate you being on the podcast because marketing had asked me to do a topic about teledentistry and I was like, oh shoot, that's like not my forte at all. so   You and I were actually chatting in the hot tub. call it Think Tank session and you and I, we have a lot of good ideas that come from that Think Tank. A lot of business. no phones. That's why. We do leave our phones out. But I was talking to Jason and this is actually a podcast we had talked about quite a while ago. Jason has a lot of information on pharmacy. And if you don't know, Jason isn't really, we were going through all of it last night. It's kind of a mock in the tub. And I think it's going to be great because I feel like this is an area, I'm working at Midwestern and   knowing about how dentists, pharmacology was surely not your favorite one. Jason actually helps a lot of dentists with their clearances. And so we were talking about it and I like it will just be a really awesome podcast for you guys to brush up on pharmacology, different things from a pharmacist's side. So Jason, welcome. Thank you. Yeah, no, we were talking about it and here's like, what should I talk about on the podcast next? I have all these different topics and she's like, what do you know? And the only real interaction I have with dentists is doing clearances for procedures. We get them all the time, which makes sense.   Lots of people are on blood thinner, I've always told Kiera, like, hey, I could talk about that. Like, that's kind of a passion of mine. I'm not a dentist. Or my name is Jason Dent. So in Hebrew, Jason means tooth. No, no, no, sorry. Nerves are getting to me. Jason means healer and Dent means tooth. So my name means tooth healer. So, here's a little set. Hold on, on, hold Can we just talk about? I brought that up before you could talk about it more. So.   My name means tooth healer but I did not become a dentist. I know you wanted me to become a dentist. did. I don't know why. I enjoy medicine. I know what you're going to get to already. The things you're going to ask me. There's been years of this. But nevertheless, that's my name. We'll get that out of the way. But you did give me a great last name. So I mean, it's OK. You're All is fair and love here. SEO's up for that. But yeah, Jason, I'm going to get you right into the show. And I'm going to be the host. And we're going to welcome to the podcast show. Jace, how are you?   Good, good, good. Good, good, good. So by getting into clearances, right? This is what you're kinda talking about with you know, before we get to clearances, I actually wanted Jason, for the listeners who don't know you, who haven't talked to you, who don't know, let's kinda just give them like, how did you go from, Kiera wanted you to be a dentist, to now Jason, you are on the podcast talking as our expert on pharmacy. fantastic. I've always really loved medicine, a ton. As a kid getting headaches and taking Excedrin, like you just feel like a miserable pile of crap.   and then you take two pills and all of a sudden you feel better. Like that's amazing, like how does that happen? Also getting ear aches as a kid, just being in so much pain and then taking some medicine and you start feeling a lot better. I always had a lot of appreciation for that. I've always been mechanically inclined. I went to, started doing my undergrad and took biology and learned about ATP synthase, which is a spinning enzyme that's inside the mitochondria, like a turbine engine. I used to work on small engines on my dirt bike and thought that is so cool. So I really got wrapped up into chemistry.   All the mechanics of chemistry really pulled me in. I'm not getting goosebumps. checking. I usually get goosebumps when I think about chemistry. But it's so cool. You think an engine's awesome, like pistons and camshafts and pressures, the cell is the same thing. It's not as loud, so it's not as cool. But it's fascinating. that's why we're like. ⁓   chemistry and really got into coagulation. So I did my residency after pharmacy school. we went to Arizona for three years. ⁓ You did and your main focus, you were never wanting to be the guy behind the counter. No, I haven't done that. Yeah. No, I love them though. I've always really want to go clinical. ⁓ But I love my retail ⁓ pharmacists. They're amazing resources. And ⁓ I use the retail pharmacist every day still to this day, but I went more the clinical route, really love the chemistry aspect of it.   did my doctorate degree and then I did my residency in Reno. Reno's kind That's how we got here everybody. Welcome to Reno. Strategically placed because I was really interested in critical medicine and where we're located we cover a huge area. So we pull in to almost clear, we go clear to Utah, clear to California, all of Northern Nevada. We get cases from all over. So we actually are kind like the first hub of care for lot of areas. So we really get an eclectic mixture of patients that come in that need-   all kinds of different cases that are coming to them. So it's what I really wanted. So I did my residency in critical care there. And then for the next 10 years, I worked in vascular medicine with my final five years being the supervisor of the clinic. Ran all the ins and outs of that. So my providers, two doctors were on our view. So when we talk about dentistry, talk about production, those kinds of things, totally get it. My doctors were the exact same way, my vascular providers. ⁓   There's some pains there, right? You wanna be seeing patients as much as possible, being able to help as many people, keeping the billing up. And had other nurse practitioners, four practitioners, a fleet of MAs, eight pharmacists. We also had that one location we had, going off the top of my head, I think we had eight locations running as well. And we took care of all the different kinds of vascular cases that came to us. Most common was blood clots, ⁓ which is just a...   which is an easier way of saying VTE. There's so many different ways to say a blood clot. Like you might hear patients say, I've had a PE or a DVT or a venous thromboembolism or a clot in my leg, right? They're all clots, but in different locations. Same with an MI, and MI can be a clot as well. ⁓ there's a lot of, everybody's kind of saying the same thing, but sometimes the nomenclature can make it sound hard, but it really is actually pretty simple.   No. And Jason, I love that you went through, you've been in like, and even in your, ⁓ when you were getting your doctorate, you were in the ER. You also worked in retail pharmacy. remember you having a little sticker on your hand. And retail pharmacy, I have a lot of respect for those guys. They have a lot of pressure on them. and then you also, ⁓ what was that test that you had to take that? I don't know. You were like studying forever for it. ⁓ board certification for, ⁓ NABP. Yeah. So I did that board certification as well.   And now you've moved out of the hospital side onto another section in your career. Now in the insurance, right? So it's really, really interesting. So now I'm on the other side reading notes and evaluating clinical appropriateness and trying to help patients with getting coverage and making those kinds of determinations. So yeah, I've really jumped all over. Really love my clinical days. I know. don't I don't I do miss them. But yeah, kind of had a good exposure to a lot of.   pharmacy a lot a lot of dentists actually with all the places that come through which Jason I really appreciate that and honestly I know you are my spouse and so it's fun to have you on but when I go into conversations like this I don't know any of this information and so finding experts and Jason I think here's me talk more about dentistry and my business than I do hear about him on pharmacy so as we were chatting about this I really realized you are a wealth of knowledge because you've been on the clinical side so you've done a lot of patient care and you've seen how   medications interact and I know you've had a few scares in your career and ⁓ you've known some physicians that have had a few scares and ⁓ you've seen plenty of patients pass away working in the ER and gosh in Arizona drownings were such a big deal. I remember when you were in the ER on your rotations I'd be like who died today? Like tell me the stories and you've really seen and now going on to the insurance side I felt like you could just be such a good wealth of knowledge because I know dentists are sometimes so   I would say like maybe just a little more anxious when it comes to medications. I know that dental students from Midwestern were like here was like four months and we had to like pass it, learn it. And Jason, you've done four years plus clinical residency, plus you've been in it. And something I really love about Nevada Medicine is they've been so collaborative with you.   like your heart, your cardiologist, they diagnose and then they send to you to treat with medicine and... Yeah, I've been really lucky being here in Reno too. The cardiology team has been amazing to work with. We started a CHF program, sorry, congestive heart failure program for patients. So we would collaborate with cardiologists. They'd see the cardiologists and then they send them to the pharmacist to really manage all the medications. So there's pillars of therapy ⁓ called guideline directed medical therapy and the pharmacist would take care of all that. So that's gonna be your...   your beta blockers, your ACEs, your ARBs, your Entresto, which would be a little bit better, spironolactone. So just making sure that all these things are dosed appropriately, really monitoring the heart, and make sure that patients are getting better. we've had real positive outcomes when the, sorry, this is totally off topic. do, talk about that study. When we looked at when patients were coming to see our pharmacists in our clinic that we started up, the patients were half as likely to be readmitted. And this was in 2018, and our pharmacists,   We're thinking about all the medications. We're usually adjusting diabetes medications too at the same time. Just kind of naturally just taking care of all the medications because we kind of got a go ahead from the providers, a collaborative practice agreement that we could make adjustments to certain medications within certain parameters. So we weren't going rogue or maverick, but we were definitely trying to optimize our medications as much as possible. And then years later, some studies came out with, I'm sure you've seen Jardins and Farseegh. not trying to, I'm not.   I don't get any kickback from them. I have no conflicts to share. But because our pharmacists were really optimizing that medication, those medications were later shown to reduce hospitalizations and heart failure, even though they're diabetes medications. Fascinating. So it wasn't really the pharmacists. It was just the pharmacists doing as much as they can with all the tools that were in front of them. And then we found out that the patients were going back to the hospital.   half as much as regular patients. So, yeah, being here, it's been so amazing to work with providers here. the providers here want help, want to help patients, don't have an ego. I mean, I just, it's awesome. I love it. I do love how much I think Jason sees me geek out about dentistry and I watching Jay's geek about his pharmacy and how much he loves helping patients. And ⁓ really that was the whole idea of, all right.   Dentistry has pharmacy as a part of it. And I know a lot of dentists are sending in clearances and I know working in a chair side, it would be like, oh no, if they're on warfarin or on their own blood clot, you guys, honestly don't even know half of what I'm talking about because this is not my jam, which is why Jason's here. But I do know that there was always like, well, we got to talk with their provider. And so having Jason come in and just kind of explain being the pharmacist that is approving or denying or saying yes or no to take them off the blood thinners in different parts, because you have seen several dental   I don't know what they're called. What is it? Clarence's? that what comes to you? don't even know. All day my mind, it's like, here is the piece of paper that gets mailed to you to the pharmacist and then you mail it back. So whatever that is. But Chase, let's talk about it because I think you can give the dentist a lot of confidence coming from a pharmacist. What you guys see on that side. When do you actually need to approve or disapprove? Let's kind of dig into that. Yeah. Well, first of all, I think I'm not a replacement for any kind of clinical judgment whatsoever. Every patient's different. But the American Diabetes Association, you   I work with diabetes a lot. American Dental Association has some really great guidelines on blood thinners and I would always reference them. I actually looked at their website today. Make sure I'm up to speed before I get back on this again. They have resources all around making decisions for blood thinners. And I think the one real important thing in putting myself in the shoes of a dentist or any kind of staff that's around a patient that's in a chair, if they say I'm on a blood thinner, right, a flag goes up. At least in my mind, that's what goes up.   Like, okay, how do we get across this bridge? And I think the important thing to really distinct right then when they say they're on a blood thinner is that is kind of a slang word for a lot of different medications, right? Like it's the overarching word that everybody pulls up saying, I'm on a blood thinner. It's like, okay, but I don't know what say. It's like, I have a car. You're like, okay, do you have a Mazda? Do you have?   Toyota, Honda, what do you have? or even worse it'd be like saying I have a vehicle, right? So when somebody says they're on a blood thinner, it opens up a whole box of possibilities of what they're Blood thinners are also, doesn't, when they're taking these types of medications that are quote unquote a blood thinner, it doesn't actually thin the blood, like adding water to the blood, if that makes sense, or like thinning paint, or like thinning out a gravy, right? It doesn't do the same thing. Blood thinners, really what they're doing is they're working on the blood, which.   which is really cool, try not to tangent on that. ⁓ When they're working on the blood, it's not thinning it per se, but it's making it so that the proteins or platelets that are in it can't stick together and make a cloth quite as easy. So whenever somebody's on a blood thinner, I usually ask, what's the name of the blood thinner that you're on? It's not bad that they use that slang, that's okay, on the same page, but it's really broken into two different classes. There's anticoagulant and antiplatelet.   And a way to kind of remember which is which, when residents would come through our clinics, the way that I teach them is a clot is like a brick wall. You know, it's not always a brick wall. Usually the blood is a liquid going through. But once they receive some kind of chemical message, it starts making a brick wall with the mortar, which is the concrete between the and the bricks, the two parts. When it's an anti-quagent, it's working on that mortar part. When it's an anti-platelet, it's working on the bricks part, right? You need both to make a strong clot or strong brick wall.   But if you can make one of them not work, obviously like if your mortar is just water, it's not working, right? You're not gonna make a strong brick wall. So that's kind of the two deviants right there. So that's what I do in my mind real quickly to find out because antiplatelets are usually, so that's gonna be like your Plavix, Ticagrelor, Brilinta. And hold on, antiplatelets are bricks? Good job, bricks. They're the bricks. And so the reason I was thinking you could remember this because I'm, antiplatelets, it's a plate and a plate is more like a brick.   And anti coagulant, I don't know why quag feels like mortar to me, like quag, like, know, it's like slushy in the blood, like it's coagulating. It's a little bit of that, like, honestly, I'm just thinking like coagulated blood is a little bit more mortar-ish. And so platelet is your plate, like a brick, and anti-quag is like.   the gilly between the bricks. Okay, okay, I got it. Yeah, so there's an exception to every rule, but when they're on that Don't worry, this is Kiera, just like very basic. You guys are way smarter listening to this, and that's why Jason's here. No, no, you helped me pass pharmacy school. When we were doing all the top 200, you helped me memorize all know what flexorill is, all right? That's a muscle relaxant. Cyclo? I don't know that part. It's a cyclo, because you guys are cycling and flexing. I don't actually know. just know it's a muscle relaxant, so that's about as far as I got. When we're looking at antitick platelets, so that's the brick part, so that's going to be your, you know,   Hecagrelor, Breitlingta, Clopidogrel is the most common one. It's the cheapest one, so probably see that one the most. Those, I mean, there's an exception to every rule, but that's generally being used after like a stent's placed in the heart. It can be used for VTE, there's some out there, but that's pretty rare. But also for some valves that are placed in the hearts, it can be used for that as well. So antiplatelet, really thinking more like a cardiac event, right? Like I said, there's always an exception to every rule, but that's kind of where my mind goes real quickly, because we're gathering information from the patient.   They're on anticoagulant. Those are like going to be the new ones that you see commercials for all the time. So Xeralto, Alequis, those are the two big ones right now. They're replacing the older one. And also we were supposed to do a disclaimer of this is current as of today because the ADA guidelines do change. this will be current as of today. And Jason, as a pharmacist, is always looking up on that. I had no clue that you are that up to speed on dental knowledge. so just throwing it out there that if you happen to catch his podcast,   a few years back that obviously check those guidelines for sure. But the new ones are the Xarelto and Eloquist. They're replacing the older ones of warfarin. Warfarin's been around for a really long time. We've seen that one. Those are anti-coagulants. So when you're looking, when a patient says that, generally they're on that medication because they've possibly had a clot in the past or they have a heart condition called atrial fibrillation. Those are kind of the two big ones. Like I said, there's always caveats to it, but that's kind of where my mind goes real quickly. And then,   as far as getting patients cleared, the American Dental Association has really good resources on their website. You can look at those and they're always refreshing that up. They even say in their own words that there's limited data around studying patients in the dental chair and with anticoagulants or anti-platelets. It's pretty limited. There's a few studies, some from 2015, some from 2018. There's one as recent as 2021, which is nice. But really, all of those studies come together and it's really more of an expert consensus.   And with that expert consensus, they have kind of simplified things for dentistry, which is really nice. ⁓ comparing that to, we have more data for like total hip replacement, total knee replacement. We have a lot of data and we know really what we should be doing around then. But going back to dentistry, we don't have as much information, so they always say use clinical judgment, but they do give some really great expert guidance on that. So if a patient's on an anticoagulant, ⁓   they generally recommend that it doesn't need to be stopped unless there's a high bleeding risk for a patient. as a provider or as a clinician in the practice, you can be looking at high bleeding risk. Some things that make an oral procedure a little bit lower risk is one, it's in the compressible site, right? Like we can actually put pressure on that site. That's the number one way to stop bleeding is adding pressure. It's not like it's in the abdominal cavity where we can't get in and can't apply pressure. So number one, that kind of reduces the bleeding risk.   is number one. Two, we can add topical hemostatic agents. Dentists would know that better than me. There's a lot of topical ways to do that. So not only pressure, but there's those things as well. And also, but there are some procedures that are a little bit more likely to bleed. And that's where you and dentists would come in hand in What's the word in APO? Oh, the APOectomy. I got it right. Good job. like, didn't you tell me last night that the ADA guideline was like what?   three or four or more teeth? great question. So you can extract one to three teeth is what their expert consensus One to three teeth without. Without really managing or stopping anticoagulation or doing anything like that. I think that's some good guidance from them. I'm gonna add a Jasonism on that though. So with warfarin, I do see why dentists would be a little bit more conservative or worried about stopping the warfarin because warfarin isn't as stable as these newer agents. Warfarin, the levels.   quote unquote levels can go really high, they can go really low. And if the warfarin levels are high, they're more likely to bleed. So I do think it makes sense to have a really recent INR. That's how we measure what the warfarin's doing. I think that makes a lot of sense, but the ADA guidelines really go into the simplification version of all these blood thinners. Generally, it's recommended to not stop them because the risk of stopping them outweighs the benefit of stopping them in almost every case. Almost every case.   ⁓ So when you're with that patient, right, they say I'm on a blood thinner, finding out which kind of blood thinner that they're on, you find out that they're on Xeralto, right? How long have you been on Xeralto for? I've been on it for years. You don't know exactly why, but if they haven't had any recent bleeding, you're only gonna remove one tooth. ⁓ You can do what's called a HasBlood score. That kind of looks at the bleeding risk that they'd have. That'd be kind of going a notch above, but in my mind, removing one tooth isn't a real serious bleeding risk. I'd love to hear from my dentist friends if they...   disagree, right, but ADA says one to three tooth removals, extractions, that's the fancy word. Extractions, yeah, for extracting teeth out. Is not really that invasive. Sure. It's not that high risk, so it's usually perfectly fine. So if a patient was on Xarelto, ⁓ no other, this is in a vacuum, right? I'm not looking at any other factors, which you should be looking at other factors. I would be perfectly fine to just remove one to two.   And when those clearances come in, because dentists do send them, talk about what happens. You guys were working in the hospital and you guys would get these clearances all the time. do. We get them so often. I mean, we get like four or five a day. We'd love to give it to our students, student pharmacists, and ask them what to do. And they would usually look up the American Dental Association guidelines and come up with something. We're like, yep, that's what we say too. In fact, we say it so many times a day that we have a smart phrase.   which just blows in the information real quickly and faxes it right back to the So it's like a copy paste real quick. So what I wanted to point out when Jason told me this is dentists like hearing this and learning this, this can actually save you guys a ton of time to be able to be more confident, to not need to send those clearances on. And we were actually talking last night about how I think this might be a CYA for dentists. like, as we were talking, I think Jason, you seeing so many other aspects of medicine, like you've literally seen patients die, you've seen other areas.   And so coming from that clinical vantage point, we were realizing that dentists, we are so blessed to live in an injury. I enjoy dentistry because possibly there's someone dying, not super high, luckily in dentistry. The only time that I have actually had a doctor have a patient pass away, and it was only when they were completely sedated and doing ⁓ some other things, but that was under the care of an anesthesiologist. And so that's really our high, high risk. And so hearing this, Jason,   That was one of the reasons I wanted him to come on is to give you doctors more confidence of do we have to always send to a pharmacist? I mean, hearing that on the pharmacy side, they're just sending these back and not to say to not see why a to not cover this because you might be questioning like, well, do I really need to? But you also were talking about some other ways of so number one, you guys are just going to copy back the 88 guidelines. So so 88 guidelines. Yeah. And I think that that gives a lot of confidence to a provider or a dentist is that you can go to the 88 guidelines and read them, right? Like you're listening to some   nasally monotone pharmacist on a podcast. Rumor has it, people love him at the hospital. were like, you're the voice, he's been told he has a good radio So for the clinic, I was the voice. Like, yeah, you've reached the vascular clinic, right? And they're like, oh my gosh, you're the voice. But sorry, you me distracted. That'll be your next career, Jace. You're going to be a radio host. OK. I would love that. I love music. But you're hearing from a nasally guy, but you can actually read the ADA guidelines. You just go right to the ADA, click on Resources, and under Resources, it has the   around anticoagulants, I think that's the best way to get a lot of confidence about it because they have dentists who are the experts making calls on these. I'm just reiterating what they say, but I think it makes a lot of sense to help providers. And the reason why my heart goes out to you as well is having the providers that used to work underneath me, they're always looking for our views, which is a fancy way of making sure that they're drilling and filling. Can I say that? Yeah, can say drilling and filling. They're being productive, right? They're being productive, right?   They're always looking to make sure if a patient's canceling, like get somebody in here. Like I need to be helping people all day long. That's how I, we keep the lights on. That's how I help as many people. And so if you have a patient coming in the chair and it has an issue, they say I'm on Xeralto. Well, you can ask real quickly, why are you on Xeralto? I had a clot 10 years ago. my gosh. Well, yeah, we're pretty good to go. Then I'm not worried. We're only removing one tooth or we're just doing a cavity or a cleaning. Something like that. Shouldn't be an issue whatsoever because there's experts in the dental. ⁓   in the dental society, the ADA guidelines that recommend three teeth or less, minimally invasive. They really recommend if it's gonna be really high bleeding risk. And clinically, that's where you would come in, ⁓ or yourself. know, apioectomy is one that's like on the fence line. I don't know where implants set. though, and like we were talking, implants aren't usually like a date of procedure. Most people aren't popping in, having tooth pain, and we're like, let's do an implant. Now sometimes that can be the case, but typically that one's gonna have   a few other pieces involved. And so that is where you can get a clearance if you want to. ⁓ But we were really looking at this of like so many dentists that I know that you've seen will just send in these clearances because they are. And I think maybe a way to help dentists have more confidence is because you know, I love routines. I love to not have to remember things. So why don't we throw it in, have the team member set it up where every quarter we just double check the ADA guidelines. Are there any updates? Are there any other things that we need to do on that? That way you can just see like   getting into the language of this, of what do I need to do? Because honestly, you guys, know pharmacy was not a big portion for it, so, recommending different parts, but I think this is such a space where you can have confidence, and there's a few other things I wanna get to, and I you- I some pearls too. Okay, go. I'm so when she get me into talking about drugs, I'm not gonna stop. So, some other things around that too is these newer blood thinners like Xarelto Eloquist, they now have reversal agents, so a lot of providers in the past were really worried about bleeding because we can't turn it off. We can turn those off. Warfarin has reversal as well, right?   So I'm looking at these patients. It's really low risk. It's in the mouth, generally speaking. Very rarely are they a high bleeding risk. Now if you're doing maxillofacial surgery, this does not apply, right? This does not apply whatsoever. you're like general dentist, you're pediatric dentist. Yeah, yeah, and it's kind of on the fly. So just trying to really help you to be able to take care of those patients on the moment, have that confidence, look at the ADA guidelines, have that in front of you. I don't think it's a bad thing to ever...   check with their provider if you need to. If you're thinking, I feel like I should just check with the provider, I would never take that away from you. But I just want to kind of steer towards those guidelines that I have to help. But what did you want to share? No, yeah, I love that. And I think there were just a few other nuggets that we were chatting about last night that can help dentists just kind of get things passed a little bit easier. So you were mentioning that if they were named to their cardiologist, what was it? was like, who is the last? Great question. Yeah, when a patient's on a blood thinner,   It could be prescribed by the cardiologist. It could be prescribed by the family provider or could have been punted to like a vascular clinic like where I was working. It can go to any of those. And when you send that fax, right, if it goes to the cardiologist and it's supposed to go to the family care provider, like it just kind of goes, goes nowhere, right, from there. So I think it's a really good idea to find out who prescribed it last. If the patient doesn't know who prescribed their blood thinner last, you can call their pharmacy. I call pharmacies all day long.   I have noticed in the last year, they are way easier to get a hold of, which has made my job a lot easier, working on the insurance portion. So reaching out to the pharmacy, finding out who that provider is and sending it to them, because they should be able to help with that. I thought that was a good shift in verbiage that you had of asking instead of like the cardiologist, because that's who you would assume was the one. But you said like so many times you guys would take care of them, and then they go back to family practitioner, and you guys would get the clearances, but you couldn't clear because you weren't overseeing. So just asking the patient.   who prescribed their medication for them last time. That way you can send the clearance to the correct provider. then- And they might not know. You know patients, right? They're like, I don't know, my mom's or else, I don't know who gave it to me. Somebody told me I need to be on this. But at least that could be another quick thing. And then also we were talking last night about-   ⁓ What are some other things that dentists can do when like writing scripts to help them get what I think like overarching theme of everything we discussed is one how to help dentists have less I think drag through pharmacy. ⁓ Because pharmacy can take a little while and so perfect we now know the difference between anti-quag and anti-platelet. We know which medications are probably safe. We know we can check the ADA guidelines so that we were not having to do as many clearances. We also know if they're on a medication to find out and we do need a clearance.   who we can go to for the fastest, easiest result. And now, in talking about prescriptions, you had some really interesting tips that you could share with them. Yeah, so with writing prescriptions, right, pharmacies are pharmacies. So I'm not gonna say good thing or bad thing. There are challenges working with pharmacies. I'm not gonna play that down at all. ⁓ If you're writing prescriptions and having issues and kickbacks from pharmacies, there's some interesting laws around ⁓ writing prescriptions. Say that you're trying to ⁓ prescribe   augmentin, you know, 875 BID, and you tell the patient, hey, I want you to take this twice a day for seven days, and then you put quantity of seven, because you're moving fast, right? You want it for seven days, quantity of seven. Quantity would actually be 14, right? It's not that big of a deal. Anybody with common sense would say if you're taking a pill for twice a day for seven days, you need 14 tablets. But LAHA doesn't allow pharmacists to make that kind of a change, unfortunately. They have to follow what you're saying there. So you're going to get a...   An annoying callback that says, you wrote for seven tablets. I know you need 14. Is that OK? Just delays things, right? So ⁓ I really like the two letters QS. That's Q isn't queen. S isn't Sam. Yeah. It stands for quantity sufficient. So you don't have to calculate the amount of any medication that you're doing. So for me, as a pharmacist, when I was taking care of patients, I hated calculating the amount of insulin they would need for an entire month. So I would say.   Mrs. Jones needs 15, I'd say 15 units ⁓ QD daily. ⁓ And then I say QS, quantity sufficient, ⁓ 90 day supply through refills. So the pharmacy can then go calculate how much insulin that they need. I don't have to even do that. So anytime you're prescribing anything, I like that QS personally. So that lets the pharmacy use ⁓ common sense, as I like to call it, instead of giving you a call. I think that's super helpful. I also thought of one thing too.   going back to blood thinners is when it's kind of like a real quick, like they're not gonna have you stop the blood thinner at all. like you're seeing if you can stop the blood thinner for a patient, there's some instances it's just not gonna happen. And that's whenever they've been, they've had a clot or a stroke or a heart attack within the last three months. Three months. Yeah, that's kind of like the.   Because so many people are like, they had a heart thing like six years ago. And so I think a lot of my dentists that I worked with were like, we got to stop the blood thinners. But it sounds like it's within three months. Yeah, well, I'm just the time. Like this is general broad strokes. What I'm just trying to say is when you want to expect a no real quick. Got it. Right. So because benefits of stopping a blood thinner within those first three months of an event is very, very risky versus the, you know, the benefit of reducing a little bit of blood coming out of the mouth. Right. Like that's not that bad.   when somebody's had a stroke or a heart attack or pulmonary embolism, a clot in the lung, like we can't replace the lung, heart or brain very easily. We can replace blood a lot better. We've got buckets of it at most hospitals have buckets of it, right? So I'm always kind of leaning towards I'd rather replace blood than tissue at all times. So that's kind of a quick no. If they've had one those events in the last three months, we are really, really gonna watch their brain instead of getting.   root canal, right? Like really worried about them. So you'll just say no. And they could the dentist still proceed with the procedure or would you recommend like a three month wait? Or is it provider specific way the pros and cons because sometimes you need to get that tooth out. Great question. think then it's going to come into clinical. That's that's when you send in the clearance, right? Like, and it's great to reach out to the provider who's managing it for you. But I think it's kind of good to know exactly when you get a quick no quick no is going to be less than three months.   ⁓ Or when it's going to be like a kind of a typical, yeah, no problem. If it's been no greater than six months, they're on the typical anticoagulants or alto eloquence. Nothing crazy is going on for them. You're only removing two teeth. This is very, very low risk. But again, I'd urge everybody to read the ADA guidelines. That way you feel more comfortable with it. I'm not as eloquent as they do. They do a real good job. So I don't want to take any of their credit. I think they do a real good job of simplifying that and making you feel confident with providing.   more timely care for patients. Which is amazing. And Jayce, one last thing. I don't remember what it was. You were talking about the DEA and like six month rule. yeah. Let's just quickly talk about that and then we'll wrap this because this is such a fascinating thing for me last night. Yeah. So when comes to prescribing controlled substances, most providers have to have a DEA license. OK. First of all, though, what's your take on dentist prescribing controlled substances? ⁓ I don't think, you know, I worked on the insurance side of things. Right. And I look at the requirements for the   as the authorizations, what a patient, the criteria a patient needs to hit in order to qualify for certain medications. A lot of times for those controlled substances, they have pretty significant issues going on, like fibromyalgia or cancer-related pain or end-of-life care versus we don't, in all my scanning thread, I don't have a ⁓ perfect picture memory. Sure. But I don't usually see oral.   pain in there. There is some post-operative pain that can be covered for those kind of medications but I really recommend to keep those lower and in fact in a lot of our criteria it recommends you know have they tried Tylenol first, they tried, have they filled NSAIDs or are they contraindicated with the patient. So really they should be last line for patients in my two cents but there's always going to be a caveat to the rule right? Of course. comes through that has oral cancer and you're taking   like that would make sense to me. Got it, so then back to the DEA. Yeah, okay. Okay, ready. So as a provider, you should be checking the, if you're doing controlled substances, you should be checking the prescription drug monitoring program, or sometimes called the PDMP, looking to see if patients are getting ⁓ controlled substances from another provider. So it's really just a check and balance to make sure that they're not going from provider to provider to getting too many narcotics and causing self harm or harm to others.   And so with checking that PDMP before prescribing, I think a lot of providers do that. A lot of softwares that I'm aware of, EMRs, electronic medical records, sometimes have links so that you can do that more quickly. However, I don't think it's as intuitive that they need to be checking that every six months in some states. And like here in Nevada, you're supposed to be checking it every six months, not for a patient, but for your actual DEA registration to see if anybody else is prescribing underneath you. Because if you don't check that every six months, you could get in some serious trouble with...   not only DEA, but even more the Board of Pharmacy and your state. Now, I don't know all 50 states, so I check with your state to see if you need to be checking that every six months, but set an alarm just to check that real quickly, keep your nose clean. ⁓ I've had providers, I've had to remind to do that. And if somebody was using your account, prescribing narcotics, you'd never know unless you went and checked that PDMP.   Yeah, I remember last night you were like, and if that was you, I would not want to be you. The Board of Pharmacy is going to be real excited to find you. So that was something where I was like, got it. So, and we all know I'm big on let's make it easy. And Jason, I love that you love this so much and you just brought so much value today. And like also for me, it's just fun to podcast. fun. Yeah. But I got a nerd out on my world a little bit. Bring it into yours. I work with dentists or at least you know, when I was working in Vascular Clinic all day long. Great questions that would come through. Yeah.   So I think for all of us, as a recap on this is number one, I think setting yourself ⁓ some cadences. So maybe every quarter we check our ADA guidelines and we check our, what is it, PDMP. PDMP. so each state, so they call it Prescription Drug Monitoring Program. We need that. Yeah, but there are different acronyms in different states, though. That's just what it's called in Nevada. I forget what it is in California, but you can check your state's prescription monitoring program, make sure that opioids aren't being prescribed under your name. Got it. So we just set that as a cadence.   We know one to three teeth most likely if they're on a blood thinner is According to the 88 as of today is good to go You know things that are going to get a quick know are going to be within the last three months of the stroke the heart attack or the Clot I'm thinking like the pulmonary embolus. Yeah, that's what we're trying to prevent   Those are gonna be quick knows and then if we're prescribing, let's do QS. We've got quantity is sufficient so that we're not getting phone calls back on those medications that we are. And then on narcotics, just being a bit more cautious. Of course, this is provider specific and in no way, or form did Jason come on here to tell you you are the clinical expert.   Jason's the clinical expert on medications. And if you guys ever have questions, I know Jason, you geek out and you want to talk to people so that anyone wants to chat shop. Be sure to reach out and we'll be able to connect you in. we've even talked about possibly, so let me know listeners. You can email in Hello@TheDentalATeam.com of ask a pharmacist anything. I talked to Jason. I was like,   We'll just have them like send in questions and maybe get you back on the podcast or we do a webinar. But any last thoughts, Jace, you've got of pharmacy and dentistry as we as we wrap up today? No, I think that's pretty much it. So check the ADA guidelines. I think it's really good to have cross communication between professions. Right. If you're working with the pharmacy, CVS, Walgreens or something like that or Walmart, I know that it can be challenging. Right. They're under different pressures. You're under different pressure. So I think ⁓ just coming in with an understanding, not being angry at each other.   you know what mean, is super beneficial and working together. When it comes to it, every dentist that I've talked to is actually worried about their patient. Every pharmacist that I've worked with is really worried about the patient as well. So we're trying to accomplish the same thing, but we have different rules and our hands are bound in different ways that annoy each other, right? Like I know Dr. Jones, want 14 tablets, but you said seven. And I know Common Sense says I should give them 14, but I've got to make that change.   knowing that their hands are tied by the law. They can't use as much common sense, which is aggravating. I mean, that's why I love what I gotta do here. I gotta just kind of help a lot more and use common sense and improve patient care. But those kinds of things I think are really beneficial as you work together and then not being so afraid of blood thinners, right? So I think those guidelines do a great job of giving you confidence and not worrying about the side effects. And there's a lot of things that you can do locally for bleeding.   You have a lot of control over that. I think that's pretty cool, the tools they have. Yeah. And at the end of the day, yes, you are the clinician. You are the one who is responsible for this. so obviously, chat, but I think collaborating, talking to other pharmacists, talking to them in your state, finding out what are the state laws, things like that I think can be really beneficial just to give you peace of mind and confidence. And again, dentistry, are maybe a bit more risk adverse because luckily we don't have patients dying That's great thing. Yeah, that's fantastic. I want my dentists to be risk adverse. I think so too. But Jason, I appreciate you being on the podcast today.   And for all of you listening, ⁓ more confidence, more clarity, more streamline to be able to serve and help our patients better. if we can help you in any way or you've got more questions, reach out Hello@TheDentalATeam.com. And as always, thanks for listening. I'll catch you next time on the Dental A Team podcast.  

On this week's episode of  The Business of Watches, we sit down with Ilaria Resta, the Chief Executive Officer of Audemars Piguet.  Among the strategically important years in the brand's 150-year history, 2025 may rank among the most significant. Not only did it mark a century-and-a-half anniversary, it demanded a strong and determined leader to navigate through a mille feuille of challenges. Amid U.S. tariffs, record prices for gold, an extremely strong Swiss franc, and an overall downturn in market demand, Resta and her team from Le Brassus grew sales by double-digits, up 12%, as of the end of October compared to the year before, according to the brand. That's more than CHF 2.3 billion in sales, according to analyst estimates. That's no small achievement considering the extraordinary headwinds facing the industry. Overall, Swiss watch exports are set to decline for the second year in a row in 2025. Under Resta's leadership, AP is bucking the trend and then some. In this episode, we talk about the notable product releases from AP this year, including its innovative perpetual calendar and the highly wearable, groundbreaking RD#5; how she intends to manage production; the evolution of the brand; and possible changes to model lines. A long-time senior executive in the consumer goods industry, Resta discusses what makes the watch industry unique and what it needs to do to appeal to the next generation of clients.Show Notes3:50 Audemars Piguet at Dubai Watch Week5:27 AP Perpetual Calendars in 38mm 7:50 Book round-up featuring Audemars Piguet The Watch 9:10 Swiss Watch Exports11:52 Royal Oak Offshore 15:30 Audemars Piguet says CEO Staying (BoF) 17:33 AP Certified Pre-Owned 19:30 Dubai Watch Week CEO Roundtable 22:25 A Plea For Proportionality (Hodinkee)